0001179110-21-000562.txt : 20210112
0001179110-21-000562.hdr.sgml : 20210112
20210112191025
ACCESSION NUMBER: 0001179110-21-000562
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210108
FILED AS OF DATE: 20210112
DATE AS OF CHANGE: 20210112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Tarka Elizabeth Ann
CENTRAL INDEX KEY: 0001783037
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-31918
FILM NUMBER: 21524580
MAIL ADDRESS:
STREET 1: 111 WAVERLY CIRCLE
CITY: PHOENIXVILLE
STATE: PA
ZIP: 19460
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: IDERA PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0000861838
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 043072298
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
BUSINESS PHONE: 4843481600
MAIL ADDRESS:
STREET 1: 505 EAGLEVIEW BOULEVARD
STREET 2: SUITE 212
CITY: EXTON
STATE: PA
ZIP: 19341
FORMER COMPANY:
FORMER CONFORMED NAME: HYBRIDON INC
DATE OF NAME CHANGE: 19951211
4
1
edgar.xml
FORM 4 -
X0306
4
2021-01-08
0
0000861838
IDERA PHARMACEUTICALS, INC.
IDRA
0001783037
Tarka Elizabeth Ann
C/O IDERA PHARMACEUTICALS, INC.
505 EAGLEVIEW BLVD., SUITE 212
EXTON
PA
19341
0
1
0
0
Chief Medical Officer
Common Stock
2021-01-12
4
S
0
1745
4.189
D
18255
D
Stock Option (Right to Buy)
4.28
2021-01-08
4
A
0
51000
0
A
2031-01-08
Common Stock
51000
51000
D
Represents the number of shares of Issuer common stock required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of 5,000 Restricted Stock Units ("RSUs") on January 10, 2021. This sale is mandated by the Issuer's election under its 2013 Stock Incentive Plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
Of the reported securities beneficially owned, 15,000 shares are represented by unvested RSUs.
The stock option award was granted under the Issuer's 2013 Stock Incentive Plan. The stock option vests and becomes exercisable over a four-year period commencing on January 8, 2021. Twenty-five percent (25%) of the stock option vests and becomes exercisable on January 8, 2022 (first anniversary of the date of grant) and the balance vests in twelve equal quarterly installments over the remaining three years of the four-year period, subject to continued service with the Issuer.
/s/ Elizabeth A. Tarka
2021-01-12